Tagged with OP

China Japanese ophthalmology specialist Santen first established a China affiliate in 2005 and has grown very successfully in the past 14 years. GM of Santen Pharmaceutical (China) Co., Ltd. (hereafter, Santen China) Takayuki Yamada gives his first impressions of the Chinese market since his arrival in April 2019, Santen’s commitment to…

Opinion Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and…

Opinion Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big Pharma to adopt this technology more fully.   The beauty of artificial intelligence is that it allows one to assess both forest and tree.   A…

Asia In the past year, PharmaBoardroom has spoken to several of the most impressive female pharma leaders working in Asia today. These women are breaking new ground and managing some of Big Pharma’s most important global affiliates. Here, five of Asian pharma’s top female executives give exclusive insights into their successes…

Sweden Johan Wäborg, General Manager Nordic countries at Actelion, shares the importance of Sweden for the group due to its world-class healthcare system and community of experts as well as its national quality and health registries which make the country an ideal environment for early launches and follow-up of treatment outcomes.…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

Canada Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to driving change at a much larger level via a ‘collective impact’ approach.   When I encountered the concept of collective impact in the Stanford Social Innovation Review, I realized the possibilities lay…

Opinion Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five fundamental pillars to adopting a patient-centric approach.    We know that patient-centricity not only aids better healthcare, it also has…

Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients.   Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…

China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets.   EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…

Spain Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no exception with Galician billionaire Amancio Ortega Gaona, the 82-year-old owner of clothing empire Inditex Fashion Group, which comprises iconic brands such as Zara and Massimo Dutti, embarking upon something of a spending spree…

Europe Dentons Germany’s Peter Homberg outlines the key requirements that companies need to fulfil in order to import medical cannabis into Germany and how attitudes and legislation on the topic are shifting across Europe.   In order to import medicinal cannabis from another country to Germany, like many other countries, the…